Hormonal
Testosterone replacement therapy (TRT) reliably improves global sexual function (libido, erectile function, sexual satisfaction) in men with functional hypogonadism in the short term.
If you are an older man with confirmed low testosterone and sexual issues (low libido, erectile dysfunction), TRT (specifically starting with transdermal gel) is the recommended treatment to improve sexual function. However, you must be screened for prostate health first. Do not expect TRT to fix weight, diabetes, or bone density issues. If you want children, do not take TRT; ask about gonadotrophin therapy instead.
TRT is able to improve sexual function in hypogonadal men. ... TRT can reliably improve global sexual function in men with hypogonadism in the short term.
Why this rating
Based on RCTs (TTrials) and strong consensus (GRADE 1), though long-term benefits are uncertain.
Source
European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males
Giovanni Corona et al. · Andrology · 2020
DOI 10.1111/andr.12770
More from this paper
- Lifestyle changes, specifically weight reduction and physical exercise, are the first-line approach for overweight and obese men with functional hypogonadism because weight loss can increase testosterone concentrations.Good
- Testosterone replacement therapy (TRT) is contraindicated in men with untreated prostate or breast cancer, and is not recommended for improving cognitive function, depressive symptoms, or exercise capacity in hypogonadal men.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →